Bipolar Disorder Clinical Trial
Official title:
Multimodal Neuroimaging of Treatment Effects in Adolescent Mania
Specific Aim 1: To determine the effects of treatment with quetiapine or lithium on brain
activation in adolescents. The investigators will use functional magnetic resonance imaging
(fMRI) to examine brain activation during an attentional task.
Specific Aim 2: To determine the effects of treatment with quetiapine or lithium on
neurometabolite measures, early in their illness course. The investigators will use 1H-MRS
to identify myo-inositol (mI), N-acetyl aspartate (NAA), and glutamate (Glu) levels in
prefrontal ALN regions.
Specific Aim 3: To determine the relationships among the changes in brain activation and
neurometabolite measures, as well as symptomatic improvement in manic adolescents.
Hypotheses 1 & 2 predict that following 6 weeks of treatment with lithium or quetiapine,
manic adolescents who demonstrate symptomatic improvement will exhibit normalized
(decreased) VLPFC and ACC activation and increased activation of compensatory posterior
attentional brain areas as well as normalization of VLPFC and ACC neurometabolite measures
(increased NAA and decreased Glu levels) compared with those who do not experience
symptomatic improvement and healthy adolescents.
Hypothesis 3 predicts significant associations between fMRI activation changes (i.e.
decreased activation in VLPFC and ACC ROIs and increased activation in the posterior
attention ROI) and MRS changes (increases in NAA and decreases in Glu levels in the VLPFC
and ACC) for patients who exhibit symptomatic improvement with either treatment.
Hypothesis 4 predicts that decreases in mI levels at 1 week will be associated with lithium,
but not quetiapine, response at endpoint.
In contrast, Hypothesis 5 predicts higher baseline Cho levels will be associated with
quetiapine, but not lithium, response at endpoint.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT02855762 -
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder
|
N/A | |
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT02513654 -
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
|
Phase 1 | |
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT02212041 -
Electronic Cigarettes in Smokers With Mental Illness
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Not yet recruiting |
NCT04432116 -
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
|
N/A | |
Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
Terminated |
NCT02909504 -
Gao NARASD Lithium Study
|
Phase 4 | |
Terminated |
NCT02893371 -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
|
||
Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 | |
Recruiting |
NCT03088657 -
Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
|